Coherus Oncology, Inc. (CHRS) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Coherus Oncology, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.058 Good day, and thank you for standing by. Welcome to the Coherence Biosciences first 00:00:05.058 -- 00:00:09.725 quarter 2025 earnings conference call. At this time, all participants are in a listen-only 00:00:09.725 -- 00:00:13.751 mode. After the speaker's presentation, there will be a question and answer session. 00:00:13.751 -- 00:00:18.939 To ask a question during the session, you will need to press star 11 on your telephone. 00:00:18.939 -- 00:00:22.244 You will then hear an automated message advising your hand is raised. 00:00:22.244 -- 00:00:24.787 To withdraw your question, please press star 11 again. 00:00:24.787 -- 00:00:28.651 Please be advised that today's conference is being recorded. 00:00:28.651 -- 00:00:31.996 I would now like to hand the conference over to your speaker today, Jody Seavers, Head 00:00:31.996 -- 00:00:35.561 of Investor Relations. Please go ahead. 00:00:35.561 -- 00:00:40.107 Jody Seavers Thank you, Shannon. Good afternoon and welcome to Coheris Bioscience's first 00:00:40.107 -- 00:00:45.334 quarter 2025 earnings conference call. Joining me today to discuss our results 00:00:45.334 -- 00:00:50.641 are Denny Lamphere, Chief Executive Officer of Coheris, Brian McMichael, Chief 00:00:50.641 -- 00:00:55.368 Financial Officer, Dr. Raj Dias, Chief Medical Officer, Dr. 00:00:55.368 -- 00:01:01.234 Theresa LaValley, Chief Scientific and Development Officer, and Samir Gurkalkar, 00:01:01.234 -- 00:01:06.181 Executive Vice President, Commercial. Before we get started, I would like to remind you 00:01:06.181 -- 00:01:11.650 that today's call includes forward-looking statements regarding Coheres' current expectations 00:01:11.650 -- 00:01:17.118 about future events. These statements include, but are not limite...